Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in September

Rhea-AI Summary

Gamida Cell Ltd. (NASDAQ: GMDA) announced upcoming presentations at two virtual investor conferences in September 2021. The presentations include participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15 and the Baird’s 2021 Global Healthcare Conference on September 14. Additionally, Gamida Cell targets a BLA submission for omidubicel by year-end 2021, potentially the first cell therapy approved for blood cancer patients needing allogeneic bone marrow transplants. An IND submission for GDA-201 is also planned for Q3 2021.

BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that company management will present its corporate highlights at the following virtual investor conferences in September:

• H.C. Wainwright 23^rd Annual Global Investment Conference, September 13-15, 2021. Company presentation will be available to view on-demand beginning on September 13 at 7:00 a.m. ET.
• Baird’s 2021 Global Healthcare Conference, September 14, 2021 with a presentation at 11:25 a.m. ET.

In the fourth quarter of 2021, Gamida Cell is targeting a BLA submission for omidubicel, the first potential approval of a cell therapy for blood cancer patients in need of an allogeneic bone marrow transplant. This submission is expected to occur by the end of the year, subject to a pre-BLA meeting with the U.S. Food and Drug Administration (FDA) planned for the fourth quarter. In the third quarter of 2021, the Company is planning an IND submission to support the initiation of a Phase 1/2 clinical study of cryopreserved, off-the-shelf GDA-201 in patients with follicular and diffuse large b-cell lymphomas.

A webcast of both conference presentations will be available on the “Investors & Media” section of Gamida Cell’s website at www.gamida-cell.com, and will be available for at least 14 days following the event.

About Gamida Cell

Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTx.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to timing of initiation and progress of, and data reported from, the clinical trials of Gamida Cell’s product candidates, anticipated regulatory filings (including the submission of the BLA for omidubicel to the FDA), commercialization planning efforts, the potentially life-saving or curative therapeutic and commercial potential of omidubicel, and Gamida Cell’s expectations regarding its projected cash to be used for operating activities and cash runway. Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on our business, and including the scope, progress and expansion of Gamida Cell’s clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 9, 2021, as amended, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cell’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Gamida Cell’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell. As a result, you are cautioned not to rely on these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005027/en/

For investors:

Stephanie Ascher

Stern Investor Relations, Inc.

stephanie.ascher@sternir.com

1-212-362-1200

For media:

Rhiannon Jeselonis

Ten Bridge Communications

rhiannon@tenbridgecommunications.com

1-978-417-1946

Source: Gamida Cell Ltd.

FAQ

What is the significance of Gamida Cell's BLA submission for omidubicel?

Gamida Cell's BLA submission for omidubicel, expected by the end of 2021, could lead to the first approval of a cell therapy for blood cancer patients requiring allogeneic bone marrow transplants.

When will Gamida Cell present at the H.C. Wainwright Global Investment Conference?

Gamida Cell will present at the H.C. Wainwright Global Investment Conference from September 13-15, 2021, with on-demand viewing available starting September 13 at 7 a.m. ET.

What is the date and time for Gamida Cell's presentation at Baird's 2021 Global Healthcare Conference?

Gamida Cell's presentation at Baird's 2021 Global Healthcare Conference is scheduled for September 14, 2021, at 11:25 a.m. ET.

What clinical study is Gamida Cell planning for GDA-201?

Gamida Cell plans to submit an IND in the third quarter of 2021 to initiate a Phase 1/2 clinical study of cryopreserved, off-the-shelf GDA-201 for patients with follicular and diffuse large b-cell lymphomas.

Where can I watch Gamida Cell's conference presentations?

Gamida Cell's conference presentations will be available on-demand in the 'Investors & Media' section of their website for at least 14 days after the events.